Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vivet Therapeutics

www.vivet-therapeutics.com

Latest From Vivet Therapeutics

J.P. Morgan Notebook Day 2: Bourla Feels Pfizer's Underappreciated, GSK Prepares For Myeloma First And More

Daily round-up from the J.P. Morgan Healthcare Conference in San Francisco: GSK's first-in-class oncology opportunity, Pfizer's Bourla on underappreciated pipeline, AstraZeneca's Enhertu pricing, Amgen's genomics push, Lilly filters through deals and Medicxi's de Rubertis teases big pharma CEOs about M&A. 

Business Strategies Launches

J.P. Morgan Notebook Day 2: Bourla Feels Pfizer's Underappreciated, GSK Prepares For Myeloma First And More

Daily round-up from the J.P. Morgan Healthcare Conference in San Francisco: GSK's first-in-class oncology opportunity, Pfizer's Bourla on underappreciated pipeline, AstraZeneca's Enhertu pricing, Amgen's genomics push, Lilly filters through deals and Medicxi's de Rubertis teases big pharma CEOs about M&A. 

Business Strategies Launches

Interview: Pfizer's Smith On Building A Gene Therapy Business

Pfizer entered the gene therapy space in 2014 and now has three programs in the clinic. Robert Smith, head of Pfizer’s gene therapy unit, spoke to Scrip about the company strategy, as well as the regulatory and reimbursement landscape.

Gene Therapy Strategy

Start-Up Quarterly Statistics: Anthos, Gossamer Lead Q1 Financings; Codiak/Jazz Deal Tops Alliances

In a review of biopharma start-up dealmaking and financing activity from January through March, based on data from Strategic Transactions, Anthos completed the largest venture capital round in the first quarter, raising $250m.

Deals Financing
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Therapeutic Areas
  • Hepatic (Liver)
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Vivet Therapeutics
  • Senior Management
  • Jean-Philippe Combal, PhD, CEO
    Gloria Gonzalez-Aseguinolaza, PhD, CSO
    Susan Coles, Head, Fin.
    Anne Douar, PhD, Chief Dev. Officer
    Bernard Bénichou, MD, PhD, CMO
  • Contact Info
  • Vivet Therapeutics
    29 rue Tronchet
    Paris, 75009
    France
UsernamePublicRestriction

Register